A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Trial Profile

A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Azacitidine (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Melphalan (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Oct 2017 Planned End Date changed from 31 Jul 2021 to 14 Oct 2020.
    • 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Feb 2017 Planned End Date changed from 31 Jul 2020 to 31 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top